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Abstract
The human gastrointestinal tract presents a vastly population of microorganisms, 
called the microbiota. The presence of these microorganisms offers many benefits to 
the host, through a range of physiological functions. However, there is a potential for 
these mechanisms to be disrupted condition, known as dysbiosis. Recent results are 
showing important associations between diabetes and the gut microbiota and how 
the intestinal flora can influence the prognosis of this illness. Microbial intestinal 
imbalance has been linked to alterations in insulin sensitivity and in glucose metabo-
lism and may play an important role in the development of diabetes. Metformin is one 
of the most important and widely used first-line medications for the management of 
type 2 diabetes (T2D). It is a complex drug with multiple sites of action and multiple 
molecular mechanisms. In recent years, attention has been directed to other modes 
of action, other than the classic ones, with increasing evidence of a major key role of 
the intestine. By analysing the effects of metformin on the homeostasis of the micro-
biota of diabetes patients, our present topic becomes one of the major importance 
in understanding how metformin therapy can improve gut microbiota dysbiosis and 
thus provide a better outcome for this illness.
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1. Introduction
The human gastrointestinal tract hosts a complex population of microorgan-
isms. The function and composition of the gut microbiota vary from an individual 
to another, factors contributing to its differences being various. The mode of 
birth, the type of diet, exercise, body mass index, different diseases and therapies 
are factors that influence the gut microbiota composition and function. Type 2 
diabetes (T2D), a highly prevalent metabolic disease, is lately characterized as 
a disease with significant alteration of the composition and function of the gut 
microbiota. New therapeutic targets are revealed, and researchers are thoroughly 
exploring these possible pathways and hypotheses to understand the pathogeny of 
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the disease better and also to better manage the treatment options. Metformin, one 
of the most widely used first-line medication for the management of type 2 dia-
betes, looks to present other modes of action than the classic ones involving liver 
metabolism. Studies proved that metformin could modulate the gut microbiota 
disturbances encountered in type 2 diabetes, in this way improving the outcome of 
the disease.
1.1 The gut microbiota: definition, development and structure
Among other things, the cohabitation of the man with the environment is at 
the root of the human evolution, an extraordinary example in this sense being the 
relationship between humans and microorganisms.
The digestive tract hosts a complex, vast and dynamic community of microor-
ganisms, called the microbiota. Together they form a mutualist relationship, with 
profound implications for the host both during homeostasis and disease [1].
It is worth mentioning that the gut is not the only place where there is a popula-
tion of microorganisms with which the human organism is in such a connection 
(e.g., the skin also harbouring a plethora of bacteria) [2].
The composition of the microbiota varies from individual to another but also 
from segment to segment of the digestive tract and includes species from all three 
domains of life: bacteria, Archaea and Eukarya. All of the species are classified into 
12 different phyla, of which more than 90% belong to Actinobacteria, Bacteroidetes, 
Firmicutes and Proteobacteria [3].
The process of colonizing the digestive tube with microorganisms is classically 
believed to begin at birth by “seeding” the newborn with microorganisms originat-
ing from the mother’s genital area (vaginal passage, mother’s areola), the skin, and 
the microbiota of the contacts in the surrounding environment, and from then the 
development continues throughout life. In recent years, however, this theory is 
challenged by a series of studies that have shown the presence of microorganisms 
in uterine tissues (e.g., the placenta, suggesting that colonization could be initiated 
before birth, by haematogenous sowing) [4]. At the age of 3–4 years, the core of 
the microbiota is relatively defined, and its structure is similar to that of the adult 
but is continuously subject to change depending on various external and internal 
factors.
Even if the core of the microbiota is established from an early age, several factors 
contribute to carve its form, explaining its variations from an individual to another [5]:
• Type of birth
• Gestational age
• Diet (starting with breast milk that plays an essential role in the development 
of the flora)
• Ageing
• Geographic region and cultural habits
• Physical activity
• Diseases
• Drugs (especially antibiotic therapy)
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As stated before, the composition also depends on the digestive tract region 
(biogeography), this being explained by the physiological properties of the digestive 
segment. For instance, in the small intestine, the pH is lower and the transit time is 
shorter, which is why only rapidly growing bacteria, with the ability to adhere to the 
surface, are thought to survive. On the other hand, the colon shows a favourable envi-
ronment for the development of microorganisms. It is worth mentioning that there 
are differences in the composition between faecal/luminal and mucosal bacteria [6].
In its final form, this whole microsystem consists of over 2000 species, which 
make up altogether more than 100 trillion cells, about 10 times more than the cells 
of the human body, hence the name of “superorganism”.
1.2 Functions
The microbiota exerts a significant influence on the host during homeostasis and 
disease, with profound implications for the proper body’s physiological functions, 
considering the microbiota as a “forgotten organ”.
The leading roles of the gut flora are the following:
• Mechanic barrier—strengthening the gut integrity, shaping and regenerating 
the intestinal epithelium, protecting against pathogens [7]
• Biologic active barrier—consuming the feeding substrates for pathogens [7]
• Key regulators of digestion—involvement in the metabolism of biliary salts, 
short-chain fatty acids (SCFAs), lipids and glucides [8]
• Harvesting energy [9]
• Regulating host immunity [10]
• Synthesis of vitamins—principal reservoir for B complex vitamins [11]
• Synthesis of dopamine, serotonin and other neurotransmitters [12]
1.3 Dysbiosis: definition, causes and consequences
Any perturbation of the healthy gut microbiota that disrupts the mutualist 
relationship between the organism and the associated microbes is called dysbiosis. 
The antagonist term of dysbiosis is eubiosis.
The underlying cause of a gut dysbiosis may be the following [13]:
• Unbalanced diet
• Drug therapy: antibiotics, chemotherapy, antiviral drugs and hormone therapy
• Diseases: cancers, hepatopancreatic diseases and diabetes
• Chronic and acute infections
• Local inflammation




The effects of dysbiosis are reflected in the processes of the internal environment, 
contributing to the emergence of numerous pathological conditions such as [14]:






• Neurological disorders [19]
• Prematurely ageing
2. Dysbiosis: microbiota in type 2 diabetes
The relationship between gut microbiota and diabetes is not fully understood, 
but changes in its composition and function can contribute to the onset and mainte-
nance of insulin resistance, thus influencing the prognosis of this illness. Both T2D 
patients and those that are at high risk of developing this disease seem to have an 
imbalance in the composition and function of the microbiota, just like a “metabolic 
dysbiosis”.
Analysing the literature, the main changes observed in the microbiota composi-
tion of diabetic patients are [20–23]:
• Reduced Gram-positive bacteria such as bacteria from phyla Firmicutes
• Reduced butyrate-producing bacteria, such as Roseburia and Butyrivibrio
• Decrease in bacteria that regulate intestinal permeability, such as Akkermansia 
muciniphila
• Increased Gram-negative bacteria, such as Bacteroides, E. coli and 
Proteobacteria
• Increase in various opportunistic pathogens such as Clostridium symbiosum and 
Eggerthella lenta
The Gram-negative bacteria (E. coli, Bacteroidetes and Proteobacteria) present 
lipopolysaccharides (LPS) at the surface of the membrane. Lipopolysaccharides 
are also known as endotoxins. They are large molecules consisting of a lipid and a 
polysaccharide composed of O-antigen with an outer core and an inner core joined 
by a covalent bond [24]. LPS are found to be elevated in the plasma of diabetic and 
obese patients by crossing an altered intestinal barrier (leaky gut). Accumulating, 
they trigger an inflammatory reaction called endotoxinemia. This systemic inflam-
matory response is associated with dyslipidaemia, increased blood pressure, but 
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also, with insulin resistance and earlier onset of diabetes through a variety of 
mechanisms such as [25]:
• Activation of pro-inflammatory kinases: mitogen-activated protein kinases 
and I kappa B kinase complex
• Increased expression of inflammatory proteins: tumour necrosis factor-α 
(TNFα), monocyte chemotactic protein and interleukin 6
• Impaired insulin signalling at the level of insulin receptor substrate 1
• Inhibition of glucose transport
The passage of LPS through the intestinal mucosa is due to increased intesti-
nal permeability (so-called leaky gut) that can be explained by the diminishing 
of butyrate and mucin-degrading bacteria such as Roseburia, Butyrivibrio and 
Akkermansia muciniphila. Furthermore, this epithelial dysfunction can determine 
an important translocation of intestinal bacteria into the adipose tissue, which 
maintains a low-grade inflammation and insulin resistance, process called “meta-
bolic infection” [26, 27].
2.1 Dysbiosis: microbiota in type 1 diabetes (T1D)
At the moment, the amount of information regarding an alleged link between 
gut microbiota and T1D is modest. Several studies showed similarities between the 
disturbances of the microbiota found in T2D and T1D patients: reduced population of 
Firmicutes and increased the population of Bacteroidetes and increased in intestinal per-
meability. Increased gut permeability might contribute to pancreatic β-cell damage due 
to the increased absorption of exogenous antigens such as Streptomyces toxin—strepto-
zotocin—that has tropism for pancreatic tissue and can cause lesions at its level [28].
2.1.1  Dysbiosis: protective anti-inflammatory- and anti-insulin-resistant 
mechanisms
There are also mechanisms mediated by the gut microbiota such as the produc-
tion of short-chain fatty acids and secondary bile acids (SBA) that counteract those 
pro-inflammatory- and insulin-resistant effects. These mechanisms can be affected 
in the case of dysbiosis.
SCFAs are produced from dietary fibres that are fermented by the intestinal 
bacteria. Acetate, butyrate and propionate are the three most common SCFAs. They 
exert an essential role in the metabolism of carbohydrates, lipids, in maintaining 
the integrity of the intestinal barrier and in modulating inflammatory reactions 
through a variety of functions [29]:
• Maintaining the integrity of the colon epithelium: Butyric acid is the primary 
energy source of the colon’s epithelial cells. It stimulates the proliferation but 
also the differentiation and apoptosis of the colonocyte, thus participating in 
the coordination of its life cycle. It also participates in the regulation of tight 
junction proteins (claudin 1 and zonula occludens).
• Improves carbohydrate metabolism: Propionate lowers the accumulation of 
lipids in the adipose tissue and reduces hepatic lipogenesis thus decreases the 
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insulin resistance. Propionate and acetate also stimulate the production of 
glucagon-like peptide-1.
• Anti-inflammatory role: Butyric acid plays an essential role in maintaining 
the integrity of the intestinal mucosa, preventing endotoxemia and metabolic 
infection. Butyric acid also inhibits the nuclear factor kappa-beta from the 
macrophages that cause a suppression of TNF-alpha, IL-6 and myeloperoxi-
dase activity.
At the intestinal level, bacteria metabolize primary bile acids (cholic and cheno-
deoxycholic acids) to secondary bile acids (deoxycholic and lithocholic acids). Bile 
acids are involved in multiple metabolic pathways, research over the last decades, 
demonstrating an essential role against inflammation and insulin resistance. 
Secondary bile acids contribute to a decrease in insulin resistance through:
• Stimulating the production of glucagon-like peptide-1 by binding to 
G-protein-coupled receptor 1 [30]
• Modulating glucose absorption through interaction with farnesoid X receptor 
(FXR)
• Modulating energy expenditure: increase energy expenditure in brown adipose 
tissue by activating enzyme type 2 iodothyronine deiodinase and oxygen 
consumption, thus contributing to the prevention of obesity [31]
• Increasing triglyceride clearance
• Bile acids are the major pathway for catabolism of cholesterol, thus regulating 
the metabolism of lipids
In terms of their anti-inflammatory role, lithocholic acid inhibits the release of 
pro-inflammatory cytokines TNF-alpha, IL1 and IL6 from colon epithelium [32].
3. Metformin and the gut
Metformin presents as a sophisticated drug having multiple sites of action and 
various molecular mechanisms. Lately, attention has been directed to other modes 
of action, different than the classic ones. Its action at the intestinal level was sug-
gested by the results of several studies that showed the following:
• A delayed-release formula is retained almost entirely in the gut, with minimal 
systemic absorption. It is effective at lowering blood glucose as the standard 
immediate-release formulation in individuals with type 2 diabetes [33].
• In diabetic rats, intravenous administration of metformin is less effective than 
intra-duodenal administration for lowering blood glucose levels [34].
• Human genetic studies proved that variants in SLC22A1 gene (the gene 
encoding OCT1), which reduce hepatic uptake of metformin, do not impact 
upon the efficacy of metformin to lower HbA1c in individuals with type 2 
diabetes [35].
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Regarding the effects of metformin on the gut microbiota, studies have shown 
that administration of metformin produced several changes in the composition of 
the intestinal flora such as the following [36]:
• Increase microbes from Verrucomicrobiaceae, Porphyromonadaceae, 
Rikenellaceae, Akkermansia muciniphila, and Prevotellaceae spp. moreover, 
species from Escherichia-Shigella sp.
• Decrease of the Lachnospiraceae, Rhodobacteraceae spp., Peptostreptococcaceae 
and Clostridiaceae
Furthermore by comparing the modified microbiome profile by metformin 
treatment, with the microbiome profiles under various disease situations, these 
changes have been negatively correlated with multiple diseases that have an inflam-
matory pathogenic substrate such as colitis, chronic diarrhoea and irritable bowel 
syndrome, suggesting that its anti-inflammatory proprieties can be determined 
through regulation of the microbiota homeostasis.
The main side effects of metformin are gastrointestinal: nausea, vomiting, 
diarrhoea and abdominal pain. These side effects occur most frequently at the 
beginning of treatment, and in most cases, they disappear spontaneously. The cause 
of these side effects is not fully understood and may be due to the growth of oppor-
tunistic pathogenic bacteria from Escherichia to Shigella spp. which are shown to 
increase at the beginning of treatment. If we relate to the increase of these opportu-
nistic pathogens, the further reduction of side effects can be caused by a reduction 
of the substrate to which these microorganisms are dependent (substrates provided 
by polysaccharide-degrading anaerobes) through diet and an increase of anaerobic 
mucus-associated bacteria such as Akkermansia muciniphila [37].
4. Metformin and the microbiota of type 2 diabetes
As stated before, the gut microbiota profile is profoundly modified in T2D 
patients in terms of its structure and composition. Administration of metformin 
results in improved glucose metabolism, but the way this is achieved is not fully 
understood, and its implications upon the intestinal flora are incompletely discov-
ered. Analysing data from the literature, administration of metformin causes the 
composition to change and, therefore, the physiology of the microbiota as well.
5. Metformin and Bacteroides fragilis
Administration of metformin is associated with an essential decrease in 
Bacteroides fragilis [38].
Bacteroides fragilis is an obligately anaerobic, Gram-negative, rod-shaped 
bacteria, whose essential feature in metabolic pathology is the presence of cap-
sular lipopolysaccharides. LPS are found to be elevated in the plasma of diabetic 
and obese patients and are associated with dyslipidaemia and increased blood 
pressure but also with insulin resistance and earlier onset of diabetes through a 
plenty of mechanisms that have been described previously. Colonizing mice with 
Bacteroides fragilis by transferring stool samples enriched with these bacteria 




Mechanisms by which metformin has determined the decrease of this species 
have not been elucidated but have been assumed since Bacteroides fragilis were 
reduced in mice that received stool samples from patients who had been given 
metformin.
Besides reducing Bacteroides fragilis, the bile acid glycoursodeoxycholic 
(GUDCA) is increased through decreasing the bacteria’s bile salt hydrolase activ-
ity. GUDCA is a glycine-conjugated form of the secondary bile acid deoxycholic 
acid, which has been known to have anti-inflammatory proprieties by reducing the 
levels of pro-inflammatory cytokines. Another biological function of GUDCA is to 
antagonize the farnesoid X receptor.
The FXR is predominantly found at the intestinal and hepatic tissue. Bile acids 
are the major ligands (activators) of this receptor. It is mainly involved in the 
metabolism of bile acids but also of carbohydrates and lipids.
The primary functions of FXR activation is the suppression of cholesterol 7 
alpha-hydroxylase (CYP7A1), which reduces the synthesis of bile acids (via the 
feedback mechanism, FXR is activated by bile acids and further determines the 
suppression of this enzyme, thus reducing the synthesis of bile acids). FXR inhibi-
tion produces an increase in bile acids improving metabolic endpoints due to their 
anti-inflammatory and insulin sensitivity effects [39].
6. Metformin and Akkermansia muciniphila
As stated before, the epithelial barrier of T2D patients is affected by an increase 
in its permeability (so-called leaky gut) followed by a migration of different toxins 
such as LPS in the systemic circulation causing inflammatory responses, insulin 
resistance and impaired glucose tolerance. In addition to these changes, a decrease 
in the Akkermansia muciniphila population was observed.
Akkermansia muciniphila is a mucin-degrading bacterium of the phylum 
Verrucomicrobia that resides predominantly in the mucus layer of the colon, 
where it is involved in maintaining intestinal integrity by promoting mucus 
secretion and making the barrier mechanism more stable and therefore 
decreasing its epithelial permeability. Oral supplementation with this bacterial 
population was shown to reduce intestinal permeability and improve glucose 
metabolism [40, 41].
A significant change in the composition of the microbiota under metformin 
treatment regarding intestinal permeability is represented by an increase in the 
population of Akkermansia muciniphila. The mechanism by which this process is 
accomplished is not fully understood, but it seems that these bacteria metabolise 
unabsorbable carbohydrates and mucin in short-chain fatty acids, which in turn 
will be used as fuel for goblet cells. Stimulated goblet cells will further produce 
mucin, in this way leading to the thickening of the mucus layer and thus to a 
decrease in the epithelial permeability. Besides increasing the population of A. 
muciniphila, administration of metformin is associated with an increase in the 
density of mucin-producing goblet cells probably through the indirect mechanism 
stated above [42, 43] Figure 1.
6.1 Metformin and SCAF-producing bacteria
One of the main features of the dysbiosis found in T2D patients is the decrease in 
butyrate-producing bacteria such as Roseburia and Butyrivibrio.
Butyrivibrio is a Gram-negative, anaerobic bacteria belonging to the Clostridia 
class, which was first described in the mid-twentieth century [44].
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Roseburia is a Gram-positive anaerobic bacteria member of the Firmicutes phyla 
named in honour of distinguished microbiologist Theodor Rosebury [45].
As stated above, short-chain fatty acids such as butyrate, propionate, and acetate 
are the product of gut microbiota activity, resulting from the fermentation of the 
carbohydrates that escapes the absorption process, playing an essential role in 
the process of enhancing intestinal integrity, reducing inflammation and improv-
ing the metabolism of glucose and lipids.
Significant increase of butyrate-producing bacteria, especially Butyrivibrio and 
Roseburia, is observed in T2D patients treated with metformin [43].
6.2 Metformin and probiotics
The genus Bifidobacterium is a Gram-positive microorganism, member of the 
Bifidobacteriaceae family, belonging to the great Actinobacteria phylum, one of the 
most abundant species of the gut microbiota.
Lactobacillus is a Gram-positive, facultative anaerobic or microaerophilic, 
rod-shaped, non-spore-forming bacteria that produces lactic acid from converting 
carbohydrates.
Oral supplementation of L. casei and B. bifidum, which are frequently used as a 
probiotic treatment option, alone and in combination, has been shown to improve 
insulin resistance (decreased fasting blood glucose, decrease HbA1C) and lower 
the serum lipid levels by enhancing short-chain fatty acids production, and thus 
improving the outcome of T2D patients [46].
Administration of metformin has been shown to increase the population of 
Bifidobacterium adolescentis, Bifidobacterium bifidum, and also Lactobacillus [47].
Figure 1. 
Akkermansia muciniphila mode of action [42, 43].
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6.3 Metformin and Adlercreutzia
The soybean, a legume species native from East Asia, is widely grown for its 
edible bean, which has numerous uses. It has been assumed that soy foods con-
tribute to reducing the risk of T2D and the progression of this disease in diabetic 
patients although opinions are divided by the results of studies which inform this 
theory or rather confirm it [48].
At the gut level, the main species that metabolizes soybean isoflavonoids to 
equol are the ones from Adlercreutzia. It is worth mentioning that not in all people 
isoflavonoids are metabolized to equol (so-called equol producers). It was specu-
lated that the health benefits of soy-based diets might be higher in equol producers 
than in equol nonproducers [49].
It seems that metformin treatment increases the population of Adlercreutzia in 
diabetic patients and therefore stimulating the production of equol, thus enhancing 
soy-based diet health benefits [50].
6.4 Summary of changes found after and before metformin treatment
These tables help summarise the changes found in the gut microbiota both 
before and after metformin treatment in T2D patients Tables 1 and 2.
Mechanisms before metformin Mechanisms after metformin
Decrease production of SCFAs Increased production of SCFAs
Decrease production of bile acids Increased bile acid production, especially GUDCA
Inhibition of farnesoid X receptor
Epithelial dysfunction and increased intestinal 
permeability
Enhancing the intestinal barrier, decreasing its 
permeability
Increased systemic LPS Decreased in LPS migration, reduced systemic LPS
Endotoxemia and metabolic infection Reduced endotoxemia
Inflammation Decreased inflammation
Insulin resistance Increased insulin sensitivity
Increased production of equol
Table 2. 
Summary of changes in the functions of microbiota before and after metformin treatment.
Structure before metformin treatment Structure after metformin treatment
Reduced Gram-positive bacteria, such as bacteria from phyla 
Firmicutes
Increased Firmicutes
Reduced butyrate-producing bacteria, such as Roseburia and 
Butyrivibrio
Increased Roseburia and Butyrivibrio
Decrease in bacteria that regulate intestinal permeability, such 
as Akkermansia muciniphila
Significant increase of Akkermansia 
muciniphila
Increased Gram-negative bacteria, such as Bacteroides, E. coli 
and Proteobacteria
Significant decrease of Bacteroides fragilis
Increase in various opportunistic pathogens, such as 
Clostridium symbiosum and Eggerthella lenta




Summary of changes in microbiota composition before and after metformin treatment of T2D.
11
Metformin and Its Benefits in Improving Gut Microbiota Disturbances in Diabetes Patients
DOI: http://dx.doi.org/10.5772/intechopen.88749
7. Conclusions
Alterations of the intestinal microbiota are a key element in understanding the 
pathophysiology of diabetes and maybe to explain the variability in terms of its 
therapeutic response and complications occurrence in different patients.
Metformin exerts a significant influence on the bacterial constellation found in 
the gut, bringing a significant contribution to restoring its balance.
With changes in both composition and function, modulation of the intestinal 
flora of patients with type 2 diabetes mellitus, obtained by various methods, can 
bring a better outcome of diabetes patients and can improve the morbidity and 
mortality rates of this widely present metabolic disease.
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